Ultra violet therapies for spine-related pain
A UV probe capable of providing a Th2 immune environment for the treatment of back pain.
1 . A method of treating degenerative disc disease in an intervertebral disc of a patient having a nucleus pulposus and an annulus fibrosus, comprising the steps of:
a) intradiscally administering an effective amount of a formulation comprising interleukin-10 (IL-10) into the intervertebral disc.
2 . The method of claim 1 wherein the IL-10 is autologous.
3 . The method claim 1 wherein the IL-10 is derived from the patient's blood.
4 . The method of claim 1 wherein the IL-10 is exogenous.
5 . A method of treating sciatica, comprising the steps of:
a) epidurally administering an effective amount of a formulation comprising interleukin-10 (IL-10) into the vicinity of a nerve root.
6 . The method of claim 5 wherein the IL-10 is autologous.
7 . The method claim 5 wherein the IL-10 is derived from the patient's blood.
8 . The method of claim 5 wherein the IL-10 is exogenous.
9 . The method of claim 5 wherein the formulation comprises at least 1 ng/ml IL-10.
10 . The method of claim 5 wherein the formulation further comprises TGF-B.
11 . A method of administering interleukin-10 (IL-10) to a patient, comprising:
c) obtaining from the patient cells viable capable of producing IL-10;
d) exposing the viable cells to UV-B light for a period sufficient to produce induced cells, and
e) administering the induced cells to a location in the patient, whereby the induced cells in vivo produce IL-10 at the location.
12 . The method of claim 11 wherein the cells are obtained in a syringe.
13 . The method of claim 12 wherein the syringe has an inner wall of etched glass.
14 . The method of claim 12 wherein the syringe has an inner wall containing immobilized immunoglobulin.
15 . The method of claim 12 wherein a UV light source is attached to the syringe prior to step b).
16 . An intervertebral implant comprising:
a) an ultraviolet light LED, and
b) an antenna in electrical connection with the LED.
17 . The implant of claim 16 further comprising:
c) a glass layer coating the LED.
18 . The implant of claim 17 wherein the glass layer has an etched outer surface.
19 . The implant of claim 16 wherein the LED emits UV-B.
20 . The implant of claim 16 wherein the LED comprises AlGaN.
21 . A method of treating DDD in an intervertebral disc, comprising the steps of:
a) providing a probe having a distal end portion having a UV light source,
b) positioning the UV light source within the disc, and
c) activating the light source to irradiate the disc in an amount of UV light sufficient to activate macrophages therein.
22 . A method of treating DDD in an intervertebral disc having a tear in an annulus fibrosus, comprising the steps of:
a) providing a probe having a distal end portion having a UV light source,
b) positioning the UV light source adjacent the tear, and
c) activating the light source to irradiate the disc in an amount of UV light sufficient to activate macrophages present in the vicinity.
23 . A method of treating sciatica, comprising:
a) providing a probe having a distal end portion having a UV light source,
b) positioning the UV light source in the vicinity of the exuded nucleus pulposus, and
c) activating the light source to irradiate the exuded nucleus pulposus in an amount of UV light sufficient to activate macrophages present in the vicinity.
24 . A method of treating a facet joint, comprising:
a) providing a probe having a distal end portion having a UV light source,
b) positioning the UV light source within a synovium of the facet joint, and
c) activating the light source to irradiate the synovium in an amount of UV light sufficient to activate macrophages and lympocytes present in the synovium.
25 . A probe for treating spine-related pain, comprising:
a) a fiber optic cable, and
b) an inducing coating upon the fiber optic cable,
wherein the inducing coating is capable of inducing a macrophage to emit an anti-inflammatory cytokine.
26 . A method of treating facet joint pain, wherein IL-10 and TGF-B are intrasynovially admininstered in amounts effective to produce a synergistic reduction in lymphocyte activity in the synovium.
27 . A method of treating degenerative disc disease, wherein IL-10 and TGF-B are intradiscally admininstered in amounts effective to produce a synergistic reduction in lymphocyte activity in the disc.